title: Sympathetic activation on effort in patients with chronic heart failure. Long term effects of captopril.
abstract: Ten patients with congestive heart failure (CHF) (NYHA II-IV) on adjusted doses of digitalis and diuretics underwent a careful clinical assessment including an evaluation of exertion dyspnoea and the usual echocardiographic indices of cardiac performance. A cardiopulmonary exercise test with an increment of 20W every 3 minutes was prolonged until exhaustion. Systemic arterial pressure, ECG, VO2, VCO2 and VE were monitored throughout. Gas tensions, plasma catecholamines and lactate were measured in blood samples taken at the first and third minute of each exercise stage. The above measurements were carried out before and after 3 months of treatment with Captopril, 50 mg b.i.d. or t.i.d. A highly significant correlation between arterial lactate and plasma norepinephrine (NE) was observed in each patient during both exercise tests (r = 0.77 to 0.99; p less than 0.05 at least). Left ventricular end-diastolic dimensions were reduced by Captopril (from 69.9 +/- 1.7 to 65.2 +/- 1.4 mm, p less than 0.01) along with a concomitant increase in percent fractional shortening. Most of the patients were reclassified at a lower NYHA class and a significant decrease in dyspnoea score was observed. The exercise time was significantly increased (from 11.2 +/- 1.8 to 12.9 +/- 1.9 min; p less than 0.05), but the peak values of NE, arterial lactate and VO2 were not affected by the treatment. The predicted value of VE at a VCO2 of 1 L/min, regarded as an index of dyspnoea, was significantly decreased by Captopril (from 41.4 +/- 2.9 to 38.9 +/- 2.7 L/min; p less than 0.05). The positive effects of long-term treatment with Captopril on cardiac performance in CHF are confirmed. Sympathetic activity is linked to anaerobic muscular metabolism during exercise and seems to be independent of pharmacological ACE inhibition. The discrepancy between the exercise tolerance and the peak VO2 might be explained by a better utilization of the available energy.
authors.affiliation: Istituto di Semeiotica Medica, Università di Perugia, Italy.
authors.forename: E
authors.initials: E
authors.lastname: Boschetti
authors.forename: C
authors.initials: C
authors.lastname: Tantucci
authors.forename: M
authors.initials: M
authors.lastname: Cocchieri
authors.forename: M
authors.initials: M
authors.lastname: Castellano
authors.forename: G
authors.initials: G
authors.lastname: Alunni
authors.forename: B
authors.initials: B
authors.lastname: Bruni
authors.forename: F
authors.initials: F
authors.lastname: Fortunati
authors.forename: V
authors.initials: V
authors.lastname: Grassi
mesh_terms: D000328:Adult; D000368:Aged; D002216:Captopril / Q000627:therapeutic use*; D002245:Carbon Dioxide / Q000097:blood; D002302:Cardiac Output / Q000187:drug effects; D004452:Echocardiography; D005080:Exercise Test; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D007773:Lactates / Q000097:blood; D019344:Lactic Acid; D008297:Male; D008875:Middle Aged; D009200:Myocardial Contraction / Q000187:drug effects; D009638:Norepinephrine / Q000097:blood*; D010100:Oxygen / Q000097:blood; D013564:Sympathetic Nervous System / Q000187:drug effects*
chemical_list: D007773:Lactates; D002245:Carbon Dioxide; D019344:Lactic Acid; D002216:Captopril; D010100:Oxygen; D009638:Norepinephrine